Defibrotide for the Treatment of Severe COVID-19 (NCT04652115)

🧪 Interventions in This Study

• Defibrotide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Brigham and Women's Hospital — Boston, Massachusetts

📞 Contact the Study Coordinator

Phone: (617) 632-2127

Email: Paul_Richardson@dfci.harvard.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Covid19

• Pediatric COVID Outcomes Study (PECOS) — Washington D.C., District of Columbia
• SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival — Edmonton, Alberta
• COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation — Rochester, Minnesota
• The Canadian COVID-19 Prospective Cohort Study — Calgary, Alberta
• Post Acute Sequelae of COVID-19 — Nashville, Tennessee
• Lung Structure-Function In Survivors of Mild and Severe COVID-19 Infection — Hamilton, Ontario

Explore by condition: All Covid19 clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.